Are we ready to screen for inherited susceptibility to cancer?

ONCOLOGY

Volumn 10, Issue 1, 1996, Pages 57-64

  Holtzman, Neil A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ECONOMICS; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; GENETICS AND REPRODUCTION; HUMAN; NEOPLASM; REVIEW; RISK ASSESSMENT; STANDARD;

GENETICS AND REPRODUCTION;

GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HUMANS; NEOPLASMS; RISK ASSESSMENT;

EID: 0029679636     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. Angier N : Scientists identify a mutant gene tied to hereditary breast cancer. N Y Times p 1, September 15, 1994.
2. Marx J: Gene defect identified in common hereditary colon cancer Science 262:1645, 1993.
3. Tanouye E: Gene testing for cancer to be widely available, raising thorny questions. Wall St J p B1, December 14, 1993.
4. Familial Adenomatous Polyposis (FAP). Roche Biomedical Laboratories, Center for Molecular Biology and Pathology, 1994.
5. Request for Genetic Testing, University of Pennsylvania Medical Center, Molecular Diagnosis Laboratory, 1994
6. National Advisory Council for Human Genome Research. Statement on use of DNA testing for presymptomatic identification of cancer risk. JAMA 271.785, 1994.
7. Bowcock A, Biesecker B, Collins. F, et al: Recommendations on genetic testing for breast and ovarian cancer predisposition. Am J Hum Genet 55(5):i-iv, 1994.
8. Easton DF, Bishop DT, Ford D, et al: Genetic linkage analysis in familial breast and ovarian cancer: Results from 214 families. Am J Hum Genet 52:678-701, 1993.
9. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66-71, 1994.
10. Bailey-Wilson JE, Elston RC, Schuelke GS, et al: Segregation analysis of hereditary nonpolyposis colorectal cancer. Genet Epidemiol 3:27-38, 1986.
11. Hussussian CJ, Struewing JP, Goldstein AM, et al: Germline p16 mutations in familial melanoma. Nature Genet 8:15-21, 1994
12. Knudson AG: Mutation and cancer: Statistical study of retinoblastoma. Proc Natl Acad Sci 68:820-823, 1971.
13. Hansen MF, Cavenee WK: Genetics of cancer predisposition. Cancer Res 47:5518-5527, 1987.
14. Fearon ER, Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 61:759-767, 1990.
15. Fung YT, Murphree AL, T'Ang A, et al: Structural evidence for the authenticity of the human retinoblastoma gene. Science 236:1657-1661, 1987.
16. Knudson AG: All in the (cancer) family. Nature Genet 5:103-104, 1993.
17. Rodriguez E, Sreekantaiah C, Chaganti RS: Genetic changes in epithelial solid neoplasia. Cancer Res 54:3398-3406, 1994.
18. Smith HS, Lu Y, Deng G. et al: Molecular aspects of early stages of breast cancer progression J Cell Biochem 17G:144-152, 1993.
19. Papadopoulos N, Nicolaides NC, Wei Y-F, et al: Mutation of a mutL Homolog in hereditary colon cancer. Science 263:1625-1629, 1994.
20. Abramson DH, Ellsworth RM, Kitchin FD, et al: Second nonocular tumors in retinoblastoma survivors: Are they radiation-induced? Ophthalmology 91:1351-1355, 1984.
21. Shattuck-Eidens D, McClure M, Simard J, et al: A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene: Implications for presymptomatic testing and screening. JAMA 273:535-541, 1995.
22. Cystic Fibrosis Genotype-Phenotype Consortium: Correlation between genotype and phenotype in patients with cystic fibrosis. N Engl J Med 329:1308-1313, 1993
23. Service RF: Stalking the start of colon cancer. Science 263:1559-1560, 1994.
24. Tanaka K, Wood RD: Xeroderma pigmentosum and nucleotide excision repair of DNA. Trends Biochem Sciences 19:83-86, 1994.
25. Digweed M: Human genetic instability syndromes: Single gene defects with increased risk of cancer. Toxicol Ltrs 67:259-281, 1993.
26. Caporaso N, Landi MT, Vineis P: Relevance of metabolic polymorphisms to human carcinogenesis: Evaluation of epidemiologic evidence. Pharmacogenetics 1:4-19, 1991.
27. Anttila S, Vainio H, Hietanen E, et al: Immunohistochemical detection of pulmonary cytochrome P450IA and metabolic activities associated with P450IA1 and P450IA2 isozymes in lung cancer patients. Environ Health Perspect 98:179-182, 1992.
28. Swift M, Morrell D, Massey RB. et al: Incidence of cancer in 161 families affected by ataxia-tetangiectasia. N Engl J Med 325:1831-1836, 1991.
29. American Cancer Society: Cancer Facts & Figures-1994. Atlanta, American Cancer Society, 1994.
30. Lynch HT, Krush AJ: Cancer family "G" revisited: 1895-1970, Cancer 27:1505-1511, 1971.
31. Fodor SP A, Rava RP, Huang XC, et al: Multiplexed biochemical assays with biological chips. Nature 364:555-556, 1993.
32. Peltomaki P, Aaltonen LA, Sistonen P, et al: Genetic mapping of a locus predisposing to human colorectal cancer. Science 260.810-812, 1993.
33. Powell SM, Petersen GM, Krush AJ, et al: Molecular diagnosis of familial adenomatous polyposis. N Engl J Med 329:1982-1987, 1993.
34. Weber BL, Garber JE. Family history and breast cancer: Probabilities and possibilities. JAMA 270:1602-1603, 1993.
35. Sattin RW, Rubin GL, Webster LA, et al: Family history and the risk of breast cancer. JAMA 253:1908-1913, 1985.
36. Hoskins KF, Stopfer JE, Calzone KA, et al: Assessment and counseling for women with a family history of breast cancer: A guide for clinicians. JAMA 273:577-585, 1995.
37. Futreal PA, Liu Q, Shattuck-Eidens D, et al: BRCA1 mutations in primary breast and ovarian carcinomas. Science 266.120-122, 1994.
38. Wooster R, Neuhausen SL, Mangion J, et al: Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 265:2088-2090, 1994
39. Whitby LG: Definitions and criteria. Lancet 2:819-821, 1974.
40. Caskey CT. Presymptomatic diagnosis: A first step toward genetic health care. Science 262:48-49, 1993.
41. Tambor ES, Bernhardt BA, Chase GA, et al: Offering cystic fibrosis carrier screening to an HMO population: Factors associated with utilization. Am J Hum Genet 55:626-637, 1994.
42. U.S. Preventive Services Task Force: Guide to Clinical Preventive Services: An Assessment of the Effectiveness of 169 Interventions, Baltimore, Williams and Wilkins, 1989.
43. Schneider KA: Counseling About Cancer: Strategies for Genetic Counselors. Dennisport, Massachusetts, Graphic Illusions, 1994.
44. Wexler NS: The Tiresias complex Huntington' s disease as a paradigm of testing for lateonset disorders. FASEB J 6:2820-2825, 1992
45. Lerman C, Croyle R: Psychological issues in genetic testing for breast cancer susceptibility. Arch Intern Med 154:609-616, 1994.
46. Tobacman JK, Greene MH, Tucker MA, et al: Intra-abdominal carcinomatosis after prophylactic oophorectomy in ovarian-cancer-prone families. Lancet 2:795-797, 1982.
47. Wcrtz DC, Fanos JH, Reilly PR: Genetic testing for children and adolescents: Who decides? JAMA 272:875-881, 1994
48. Adam S, Wiggins S, Whyte P, et al: Five year study of prenatal testing for Huntington's disease: Demand, attitudes, and psychological assessment. J Med Genet 30:549-556, 1993.
49. Haddow JE, Palomaki GE, Knight GJ. et al: Prenatal screening for Down's syndrome with use of maternal serum markers N Engl J Med 327:588-593, 1992.
50. Babul R, Adam S, Kremer B, et al: Attitudes toward direct predictive testing for the Huntington disease gene. JAMA 270:2321-2325, 1993.
51. Faden RR, Chwalow AJ, Quaid K, et al: Prenatal screening and pregnant women's attitudes toward the abortion of defective fetuses. Am J Publ Health 77:288-290, 1987.
52. Giardiello FM, Hamilton SR, Krush AJ: Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328:1313-1316, 1993.
53. Hennekens CH, Buring JE. Antioxidant vitamins-benefits not yet proved. N Engl J Med 330:1080-1081, 1994.
54. Andrews LB, Fullarton JE, Holtzman NA, et al (eds). Assessing Generic Risks: Implications for Health and Social Policy, chap 3, pp 165. 281. Washington, DC, National Academy of Sciences Press, 1994.
55. Holtzman NA: Proceed With Caution: Predicting Genetic Risks in the Recombinant DNA Era. pp 140-142, 174-176. Baltimore, The Johns Hopkins University Press, 1989.
56. Bekker H, Denniss G, Modell M, et al: The impact of population based screening for carriers of cystic fibrosis. J Med Genet 31:364-368. 1994.
57. Marteau T, van Duijn M, Ellis I: Effects of genetic screening on perceptions of health: A pilot study. J Med Genet 29:24-26, 1992.
58. Nowak R: Breast cancer gene offers surprises. Science 265:1796-1799, 1994.
59. Weiss R: Gene discrimination barred in workplace. Wash Post p A3, April 7, 1995.
60. Hofman KJ, Tambor ES, Chase GA, et al. Physicians' knowledge of genetics and genetic tests. Acad Med 68(8):625-631, 1993.
61. Geller G, Tambor ES, Bernhardt BA, et al. Physicians' attitudes toward disclosure of genetic information to third parties. J Law Med Ethics 21(2):108-110, 1993.
62. Geller G, Tambor ES, Chase GA, et al: Incorporation of genetics in primary care practice: Will physicians do the counseling and will they be directive? Arch Fam Med 2:1119-112S. 1993.
63. Geller G, Holtzman NA: A qualitative assessment of primary care physicians, perceptions about the ethical and social implications of offering genetic testing. Qual Health Res 5:97-116, 1994.
64. Holmes-Seidle M, Ryynanen M, Lindenbaum RH: Parental decisions regarding termination of pregnancy following prenatal detection of sex chromosome abnormality. Prenat Diagn 7:239-244, 1987.
65. Bekker H, Modell M, Denniss G, et al: Uptake of cystic fibrosis testing in primary care: Supply push or demand pull? Br Med J 306:584-1586, 1993.